Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNN4 | O15554 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
| ▸ | CYP51A1 | Q16850 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CES2 | O00748 | 2/20 | 0.40 |
| ▸ | CES1 | P23141 | 2/20 | 0.40 |
| ▸ | CA3 | P07451 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29727285 | 1.00 | KCNN4 (0.43) | KCNN4CYP3A4LMNAHSP90AA1CYP19A1 | |
| SCHEMBL14398864 | 0.86 | KCNN4 (0.43) | KCNN4CYP3A4LMNAHSP90AA1CYP19A1 | |
| SCHEMBL18802727 | 0.84 | MEN1 (0.42) | KCNN4CYP3A4LMNAHSP90AA1CYP19A1 | |
| SCHEMBL441530 | 0.81 | ALDH1A1 (0.42) | KCNN4CYP3A4LMNAHSP90AA1CYP19A1 | |
| SCHEMBL22933206 | 0.81 | KCNN4 (0.46) | KCNN4CYP3A4LMNAHSP90AA1CYP19A1 | |
| SCHEMBL11962356 | 0.80 | KIF11 (0.41) | CYP11B1CYP11B2ALDH1A1PTGS1PTGS2 | |
| SCHEMBL1328840 | 0.80 | DGAT1 (0.42) | LMNACYP11B1CYP11B2KMT2AALDH1A1 | |
| SCHEMBL21782467 | 0.80 | HDAC6 (0.42) | HDAC6HDAC3HDAC1HDAC2MEN1 | |
| SCHEMBL18701599 | 0.80 | PTGS1 (0.42) | LMNACYP2C9MEN1KMT2ACA3 | |
| SCHEMBL8696180 | 0.79 | CYP3A4 (0.42) | KCNN4CYP3A4LMNAHSP90AA1CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114671737-B | Preparation method of posaconazole main ring intermediate | 张家口市格瑞高新技术有限公司 | 2023-10-24 | — | — | CN | claimed |
| CN-114671737-A | Preparation method of posaconazole main ring intermediate | 张家口市格瑞高新技术有限公司 | 2022-06-28 | — | — | CN | claimed |
| CN-114671737-B | Preparation method of posaconazole main ring intermediate | 张家口市格瑞高新技术有限公司 | 2023-10-24 | — | — | CN | disclosed |
| CN-114671737-A | Preparation method of posaconazole main ring intermediate | 张家口市格瑞高新技术有限公司 | 2022-06-28 | — | — | CN | disclosed |
| CN-114671737-A | Preparation method of posaconazole main ring intermediate | 张家口市格瑞高新技术有限公司 | 2022-06-28 | — | — | CN | disclosed |
| US-9718817-B2 | Aryl and heteroaryl ether compounds as ROR gamma modulators | GLENMARK PHARMACEUTICALS S.A. (CH) | 2017-08-01 | — | — | US | disclosed |
| EP-3131880-A1 | ARYL AND HETEROARYL ETHER COMPOUNDS AS ROR GAMMA MODULATORS | Glenmark Pharmaceuticals S.A. (CH) | 2017-02-22 | — | — | EP | disclosed |
| US-20170022195-A1 | ARYL AND HETEROARYL ETHER COMPOUNDS AS ROR GAMMA MODULATORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2017-01-26 | — | — | US | disclosed |
| WO-2015159233-A1 | ARYL AND HETEROARYL ETHER COMPOUNDS AS ROR GAMMA MODULATORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2015-10-22 | — | — | WO | disclosed |
| EP-2300422-B1 | AZETIDINES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | EVOTEC AG (DE) | 2014-11-05 | — | — | EP | disclosed |
| EP-2300422-B1 | AZETIDINES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | EVOTEC AG (DE) | 2014-11-05 | — | — | EP | disclosed |
| US-8691804-B2 | Azetidines and cyclobutanes as histamine H3 receptor antagonists | EVOTEC AG (DE) | 2014-04-08 | — | — | US | disclosed |
| US-8691804-B2 | Azetidines and cyclobutanes as histamine H3 receptor antagonists | EVOTEC AG (DE) | 2014-04-08 | — | — | US | disclosed |
| US-20110105459-A1 | AZETIDINES AND CYCLOBUTANES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | EVOTEC AG (DE) | 2011-05-05 | — | — | US | disclosed |
| US-20110105459-A1 | AZETIDINES AND CYCLOBUTANES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | EVOTEC AG (DE) | 2011-05-05 | — | — | US | disclosed |
| US-20110105459-A1 | AZETIDINES AND CYCLOBUTANES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | EVOTEC AG (DE) | 2011-05-05 | — | — | US | disclosed |
| EP-2300422-A1 | AZETIDINES AND CYCLOBUTANES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | Evotec AG (DE) | 2011-03-30 | — | — | EP | disclosed |
| WO-2009135842-A1 | AZETIDINES AND CYCLOBUTANES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | EVOTEC NEUROSCIENCES GMBH (DE) | 2009-11-12 | — | — | WO | disclosed |
| WO-2009135842-A1 | AZETIDINES AND CYCLOBUTANES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | EVOTEC NEUROSCIENCES GMBH (DE) | 2009-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105459-A1 | AZETIDINES AND CYCLOBUTANES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | HRH4, HRH3, HRH1 | KCNN4 675/4885CYP3A4 530/4885LMNA 4520/4885 |
| US-20170022195-A1 | ARYL AND HETEROARYL ETHER COMPOUNDS AS ROR GAMMA MODULATORS | RORB, RORA, RORC | KCNN4 3969/4885CYP3A4 350/4885LMNA 4351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.